Skip to content

Evaluation of the safety and efficacy of the MHP- total hip arthroplasty

Evaluation of the safety and efficacy of the MHP- total hip arthroplasty - The MHP- total hip

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON50762
Enrollment
50
Registered
2011-12-08
Start date
2012-09-25
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hip artrosis hip wear

Interventions

Cemented total hip prosthesis

Sponsors

Zimmer Biomet
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Candidates for a total hip replacement because of arthritis of the hip. 2. Patients with a good general condition. 3. Patients willing and able to participate in the clinical trial with a 10 years follow up and who have signed an informed consent. 4. Males and females. 5. Age between 55 and 75. 6. Absence or little presence of osteoporotic bone (t>-2). 7. ASA score 1 and 2.

Exclusion criteria

Exclusion criteria: Severe comorbidities Infection

Design outcomes

Primary

MeasureTime frame
- - Stability measured with RSA at discharge, 3, 6, 12 and 24 months postoperative.

Secondary

MeasureTime frame
- Safety defined as absence of serious device related complications. - Efficacy defined as functional outcome measured with HHS and the HOOS preoperatively, 6 weeks, 3, 6 and 12 months and subsequently annually until 7 years postoperatively and at 10 years postoperatively. - Bone density measured using DEXA preoperative and 6 weeks, 1 and 2 10 years postoperative. - Quality of life measured with the SF12 preoperatively, 6 weeks, 3, 6 and 12 months and subsequently annually until 7 years postoperatively and at 10 years postoperatively..

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)